These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15504656)

  • 1. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S; Arita S
    Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
    Fukuchi T; Kanemoto K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
    Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Aug; 19(5):315-6. PubMed ID: 15276667
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain.
    Ikeda T; Ishida Y; Naono R; Takeda R; Abe H; Nakamura T; Nishimori T
    Neurosci Res; 2009 Jan; 63(1):42-6. PubMed ID: 18992286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
    Shinkai K; Yoshimura R; Ueda N; Okamoto K; Nakamura J
    J Clin Psychopharmacol; 2004 Feb; 24(1):11-7. PubMed ID: 14709941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
    Grimsley SR; Jann MW
    Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G;
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
    Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
    J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.
    Yoshida K; Higuchi H; Ozaki N
    Pharmacopsychiatry; 2007 Mar; 40(2):84-5. PubMed ID: 17447181
    [No Abstract]   [Full Text] [Related]  

  • 20. Favorable effect of milnacipran on depression induced by interferon-alpha.
    Yoshida K; Higuchi H; Takahashi H; Shimizu T
    J Neuropsychiatry Clin Neurosci; 2003; 15(2):242-3. PubMed ID: 12724470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.